At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
GSK2118436drug
Likely dose
GSK2118436 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating GSK2118436 for Melanoma. Completed, enrolled 92 participants across 23 sites in 5 countries.
Detailed Summary
BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, France, Germany, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartAug 2010
Primary CompletionJul 2011
Study CompletionJun 2016
TodayJul 2026
First PostedJun 30, 2010
Enrollment StartAug 9, 2010
Primary CompletionJul 1, 2011
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.0 years ago
Interventions
GSK2118436drug
Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.